Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Viking Therapeutics (VKTX) over the last 12 years, with Q3 2025 value amounting to $66.5 million.

  • Viking Therapeutics' Net Cash Flow rose 92928.34% to $66.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.1 million, marking a year-over-year increase of 28010.01%. This contributed to the annual value of -$28.7 million for FY2024, which is 25169.72% down from last year.
  • Latest data reveals that Viking Therapeutics reported Net Cash Flow of $66.5 million as of Q3 2025, which was up 92928.34% from -$4.0 million recorded in Q2 2025.
  • Viking Therapeutics' Net Cash Flow's 5-year high stood at $140.1 million during Q1 2024, with a 5-year trough of -$151.7 million in Q2 2024.
  • In the last 5 years, Viking Therapeutics' Net Cash Flow had a median value of $3.9 million in 2022 and averaged $3.8 million.
  • As far as peak fluctuations go, Viking Therapeutics' Net Cash Flow surged by 119584.6% in 2023, and later crashed by 39645.62% in 2024.
  • Over the past 5 years, Viking Therapeutics' Net Cash Flow (Quarter) stood at $15.1 million in 2021, then crashed by 53.11% to $7.1 million in 2022, then skyrocketed by 158.1% to $18.3 million in 2023, then tumbled by 229.08% to -$23.6 million in 2024, then soared by 381.82% to $66.5 million in 2025.
  • Its Net Cash Flow stands at $66.5 million for Q3 2025, versus -$4.0 million for Q2 2025 and $11.3 million for Q1 2025.